dc.contributor.author | Pluskal, Tomáš | |
dc.contributor.author | Torrens-Spence, Michael P. | |
dc.contributor.author | Fallon, Timothy R. | |
dc.contributor.author | De Abreu, Andrea | |
dc.contributor.author | Shi, Cindy H. | |
dc.contributor.author | Weng, Jing-Ke | |
dc.date.accessioned | 2020-04-16T14:52:36Z | |
dc.date.available | 2020-04-16T14:52:36Z | |
dc.date.issued | 2019-07-22 | |
dc.identifier.issn | 2055-0278 | |
dc.identifier.uri | https://hdl.handle.net/1721.1/124692 | |
dc.description.abstract | Kava (Piper methysticum) is an ethnomedicinal shrub native to the Polynesian islands with well-established anxiolytic and analgesic properties. Its main psychoactive principles, kavalactones, form a unique class of polyketides that interact with the human central nervous system through mechanisms distinct from those of conventional psychiatric drugs. However, an unknown biosynthetic machinery and difficulty in chemical synthesis hinder the therapeutic use of kavalactones. In addition, kava also produces flavokavains, which are chalconoids with anticancer properties structurally related to kavalactones. Here, we report de novo elucidation of the key enzymes of the kavalactone and flavokavain biosynthetic network. We present the structural basis for the evolutionary development of a pair of paralogous styrylpyrone synthases that establish the kavalactone scaffold and the catalytic mechanism of a regio- and stereo-specific kavalactone reductase that produces a subset of chiral kavalactones. We further demonstrate the feasibility of engineering styrylpyrone production in heterologous hosts, thus opening a way to develop kavalactone-based non-addictive psychiatric therapeutics through synthetic biology. | en_US |
dc.description.sponsorship | National Science Foundation (U.S.) (Grant CHE-1709616) | en_US |
dc.description.sponsorship | Pew Scholars Program in the Biomedical Sciences (Grant 27345) | en_US |
dc.description.sponsorship | Searle Scholars Program (Grant 15-SSP-162) | en_US |
dc.description.sponsorship | National Institutes of Health (U.S.) (Grant P41 GM103403) | en_US |
dc.description.sponsorship | National Institutes of Health (U.S.). Office of Research Infrastructure Programs. High-End Instrumentation (HEI) Grant Program (Grant S10 RR029205) | en_US |
dc.description.sponsorship | United States. Department of Energy. Office of Science (Contract DE-AC02-06CH11357) | en_US |
dc.language.iso | en | |
dc.publisher | Springer Science and Business Media LLC | en_US |
dc.relation.isversionof | 10.1038/s41477-019-0474-0 | en_US |
dc.rights | Creative Commons Attribution-Noncommercial-Share Alike | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | en_US |
dc.source | bioRxiv | en_US |
dc.title | The biosynthetic origin of psychoactive kavalactones in kava | en_US |
dc.type | Article | en_US |
dc.identifier.citation | Pluskal, Tomáš et al. "The biosynthetic origin of psychoactive kavalactones in kava." Nature plants 5 (2019): 867-878. | en_US |
dc.contributor.department | Whitehead Institute for Biomedical Research | en_US |
dc.contributor.department | Massachusetts Institute of Technology. Department of Biology | en_US |
dc.relation.journal | Nature plants | en_US |
dc.eprint.version | Original manuscript | en_US |
dc.type.uri | http://purl.org/eprint/type/JournalArticle | en_US |
eprint.status | http://purl.org/eprint/status/NonPeerReviewed | en_US |
dc.date.updated | 2020-02-03T20:23:45Z | |
dspace.date.submission | 2020-02-03T20:23:48Z | |
mit.journal.volume | 5 | en_US |
mit.journal.issue | 8 | en_US |
mit.license | OPEN_ACCESS_POLICY | |
mit.metadata.status | Complete | |